| Dr Karen L Smith, MD | |
|
531 Faunce Corner Rd, Dartmouth, MA 02747-1242 | |
| (508) 996-3991 | |
| Not Available |
| Full Name | Dr Karen L Smith |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 28 Years |
| Location | 531 Faunce Corner Rd, Dartmouth, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316943798 | NPI | - | NPPES |
| 3206254 | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 205305 (Massachusetts) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Steward Medical Group Inc | 2860688728 | 1404 |
News Archive
Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease, chronic kidney disease, and iron deficiency anemia, announced today that it has successfully completed an End of Phase II meeting with the U.S. Food and Drug Administration regarding the Company's lead drug candidate Soluble Ferric Pyrophosphate, a novel continuous iron-replacement therapy designed to treat iron deficiency anemia in hemodialysis patients.
MIT chemical engineers have discovered that arrays of billions of nanoscale sensors have unique properties that could help pharmaceutical companies produce drugs - especially those based on antibodies - more safely and efficiently.
A first-in-man trial of a live Listeria vaccine was reported by Advaxis Inc. The Phase I/II trial was testing Lovaxin C in advanced cervical cancer patients.
For patients who receive emergency department care for heart failure, early follow-up by a physician within 7 days after emergency department discharge is associated with lower rates of death or admissions to hospital, according to research published in CMAJ.
› Verified 8 days ago
| Entity Name | Steward Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821349317 PECOS PAC ID: 2860688728 Enrollment ID: O20130626000396 |
News Archive
Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease, chronic kidney disease, and iron deficiency anemia, announced today that it has successfully completed an End of Phase II meeting with the U.S. Food and Drug Administration regarding the Company's lead drug candidate Soluble Ferric Pyrophosphate, a novel continuous iron-replacement therapy designed to treat iron deficiency anemia in hemodialysis patients.
MIT chemical engineers have discovered that arrays of billions of nanoscale sensors have unique properties that could help pharmaceutical companies produce drugs - especially those based on antibodies - more safely and efficiently.
A first-in-man trial of a live Listeria vaccine was reported by Advaxis Inc. The Phase I/II trial was testing Lovaxin C in advanced cervical cancer patients.
For patients who receive emergency department care for heart failure, early follow-up by a physician within 7 days after emergency department discharge is associated with lower rates of death or admissions to hospital, according to research published in CMAJ.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Karen L Smith, MD 531 Faunce Corner Rd, Dartmouth, MA 02747-1242 Ph: (508) 996-3991 | Dr Karen L Smith, MD 531 Faunce Corner Rd, Dartmouth, MA 02747-1242 Ph: (508) 996-3991 |
News Archive
Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease, chronic kidney disease, and iron deficiency anemia, announced today that it has successfully completed an End of Phase II meeting with the U.S. Food and Drug Administration regarding the Company's lead drug candidate Soluble Ferric Pyrophosphate, a novel continuous iron-replacement therapy designed to treat iron deficiency anemia in hemodialysis patients.
MIT chemical engineers have discovered that arrays of billions of nanoscale sensors have unique properties that could help pharmaceutical companies produce drugs - especially those based on antibodies - more safely and efficiently.
A first-in-man trial of a live Listeria vaccine was reported by Advaxis Inc. The Phase I/II trial was testing Lovaxin C in advanced cervical cancer patients.
For patients who receive emergency department care for heart failure, early follow-up by a physician within 7 days after emergency department discharge is associated with lower rates of death or admissions to hospital, according to research published in CMAJ.
› Verified 8 days ago
Susan E Vogler, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 531 Faunce Corner Rd, Dartmouth, MA 02747 Phone: 508-996-3991 | |
Dr. Jeffrey J Michaud, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 531 Faunce Corner Rd, Dartmouth, MA 02747 Phone: 508-996-3991 | |
Dr. Stacey N Knox, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 531 Faunce Corner Rd, Dartmouth, MA 02747 Phone: 508-996-3991 | |
Dr. Vrunda Bhavsar Desai, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 535 Faunce Corner Rd, Dartmouth, MA 02747 Phone: 551-580-1966 | |
Dr. Deborah D Kelly, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 531 Faunce Corner Rd, Dartmouth, MA 02747 Phone: 508-996-3991 | |
Dr. Suzanne M Caron, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 531 Faunce Corner Road, Dartmouth, MA 02747 Phone: 508-996-3991 |